 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Hyseq, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of 2,750,000 shares of its Common Stock, all of which will be sold by the Company. The filing covers an additional 412,500 shares that will be subject to the underwriters' overallotment option. The Company expects the shares to come to market between $12 and $14 per share. Lehman Brothers Inc., Smith Barney & Co. Inc., and Fahnestock & Co. Inc., will manage the offering. Hyseq, Inc. applies the proprietary DNA array technology of its integrated HyX(SM) genomics platform to develop gene-based therapeutic product candidates and diagnostic products and tests. The Company anticipates that the net proceeds of the offering will be used to develop potential therapeutic product candidates and diagnostic tests, expand the HyGenomics(TM) Database, further develop the HyChip(TM) Module, invest in capital equipment and lease additional space to increase capacity and general corporate purposes, including working capital. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State. Copies of the prospectus contained in the Registration Statement may be obtained by written or oral request directed to Lehman Brothers Inc., c/o ADP Processing, 536 Broadhollow Road, Melville, Long Island, New York at 516-254-7106 and by facsimile at 516-249-7942. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |